Orchid Pharma lifts Enmetazobactam lifetime sales target to $2 billion
Management now expects peak revenue for its key antibiotic to hit $1-2 billion. A long-awaited out-licensing deal remains unsigned.
— 1 earlier story on Orchid Pharma Ltd. →What's new
- Lifetime revenue guidance for Enmetazobactam jumped from $200-250 million to $1-2 billion.
- Peak sales are now anticipated in the fourth or fifth year post-launch.
- No binding out-licensing agreements were signed, despite management's prior hopes.
Why this matters
The massive revision to lifetime sales targets suggests management has gained conviction in the drug's market potential. The lack of a concrete out-licensing deal leaves a gap between ambition and current commercial reality. The next test is a signed contract to validate these upgraded projections.
What we're watching
- Updates on out-licensing discussions in the US, Japan, and Latin America.
- Commissioning of the 7-ACA fermentation project in Q1 FY27.
- Progress on the pending court order for the Dhanuka Labs merger.
The full read
Orchid Pharma has aggressively revised its outlook for its flagship antibiotic, Enmetazobactam. Management now targets lifetime revenue of $1-2 billion, a massive jump from the prior $200-250 million estimate. This upgrade comes with a longer runway, as peak sales are now pushed to the fourth or fifth year of the launch cycle.
But the company failed to deliver on its hope of announcing a binding out-licensing deal during the call. Discussions remain active across the US, Japan, and Latin America. The timeline for a signature is uncertain.
Elsewhere, the 7-ACA fermentation project remains on schedule for a Q1 2027 commissioning, and the Dhanuka Labs merger is still awaiting a court order. Management is aiming for 10-15% growth in the base business with 12% EBITDA margins by FY27. The strategy is clear. The valuation of these long-term targets now hinges on securing the first major partnership.
Questions answered
- How much did Orchid Pharma increase its Enmetazobactam sales forecast?
- Management raised the lifetime revenue estimate to $1-2 billion, a substantial increase from the previous peak forecast of $200-250 million.
- When does the company expect peak sales for the drug?
- Peak sales are now projected for the fourth to fifth year following the launch, shifting from the previously expected third year.
- Were any out-licensing agreements announced during the call?
- No. Despite management's hope to disclose at least one deal, no binding agreements were signed.
- What is the status of the company's other major projects?
- The 7-ACA fermentation project is on track for commissioning in Q1 2027, while the merger with Dhanuka Labs is waiting for a formal court order.
- What are the financial targets for the base business?
- Management is targeting 10-15% growth for the base business with an EBITDA margin of 12% by FY27.
Story so far
All notes on ORCHPHARMA →- 26 May 2026 · 5:51 PM IST Orchid Pharma lifts Enmetazobactam lifetime sales target to $2 billion
- 2d ago Orchid Pharma annual profit drops to ₹45.2 crore